[go: up one dir, main page]

MX2010006284A - Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. - Google Patents

Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.

Info

Publication number
MX2010006284A
MX2010006284A MX2010006284A MX2010006284A MX2010006284A MX 2010006284 A MX2010006284 A MX 2010006284A MX 2010006284 A MX2010006284 A MX 2010006284A MX 2010006284 A MX2010006284 A MX 2010006284A MX 2010006284 A MX2010006284 A MX 2010006284A
Authority
MX
Mexico
Prior art keywords
phenylephrine
compositions
pharmaceutical formulations
transmucosal absorption
formulated
Prior art date
Application number
MX2010006284A
Other languages
English (en)
Inventor
Joseph P Reo
Dennis Nelson
David Monteith
John O'mullane
Jiansheng Wan
Mohammed A Kabir
Xiaoming Chen
Original Assignee
Schering Plough Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010006284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Healthcare filed Critical Schering Plough Healthcare
Publication of MX2010006284A publication Critical patent/MX2010006284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden fenilefrina o una sal farmacéuticamente aceptable de la misma y métodos para administrar las composiciones farmacéuticas, en donde la composición se fórmula para la absorción sintética de fenilefrina que evita el metabolismo de primer paso; las composiciones de la invención se formulan para aplicarlas a la mucosa oral de un animal para permitir un suministro sintético mejorado de la forma terapéuticamente activa de fenilefrina.
MX2010006284A 2007-12-07 2008-12-04 Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. MX2010006284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1222307P 2007-12-07 2007-12-07
PCT/US2008/085523 WO2009076165A1 (en) 2007-12-07 2008-12-04 Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption

Publications (1)

Publication Number Publication Date
MX2010006284A true MX2010006284A (es) 2010-09-07

Family

ID=40510498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006284A MX2010006284A (es) 2007-12-07 2008-12-04 Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.

Country Status (17)

Country Link
US (1) US20090280160A1 (es)
EP (1) EP2237767A1 (es)
JP (1) JP2011506337A (es)
KR (1) KR20100102632A (es)
CN (1) CN101938991A (es)
AR (1) AR069572A1 (es)
AU (1) AU2008335464A1 (es)
BR (1) BRPI0820673A2 (es)
CA (1) CA2709208A1 (es)
CL (1) CL2008003615A1 (es)
CO (1) CO6321221A2 (es)
MX (1) MX2010006284A (es)
PE (1) PE20091084A1 (es)
RU (1) RU2010127737A (es)
TW (1) TW200932208A (es)
WO (1) WO2009076165A1 (es)
ZA (1) ZA201004654B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361099B (es) * 2013-02-13 2018-11-27 Procter & Gamble Medicamento con sabor a anís.
US20190008759A1 (en) * 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20230137362A (ko) * 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
WO2018130603A1 (en) 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019021476A1 (ja) * 2017-07-28 2019-01-31 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
BR112020005948A2 (pt) * 2017-09-27 2020-12-01 Aquestive Therapeutics, Inc. distribuição intensificada de composições de epinefrina e pró-fármaco
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US20210369721A1 (en) * 2020-06-02 2021-12-02 Mohamed Hussein Hamdan Sublingual formulation for hypotension and syncope
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4623664A (en) * 1985-10-31 1986-11-18 University Of Iowa Research Foundation Oil suspended phenylephrine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2087435C (en) * 1990-08-07 1998-05-05 Scott Max Herbig Use of interfacially-polymerized membranes in delivery devices
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9422571D0 (en) * 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
NL1005394C1 (nl) * 1996-04-01 1997-10-02 Kokbing Lo Bevestigingselement en band bevestigd met bevestigingselement.
DK0946155T4 (da) * 1996-12-23 2009-05-11 Sla Pharma Ag Farmaceutisk sammensætning til behandling af fækal inkontinens
WO1999015210A2 (en) * 1997-09-26 1999-04-01 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2001089476A1 (en) * 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
WO2003019948A1 (en) * 2001-08-27 2003-03-06 Koninklijke Philips Electronics N.V. Video data processor
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030083354A1 (en) * 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) * 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US20040122107A1 (en) * 2002-09-13 2004-06-24 Fine Jeffrey R Method of alleviating barometric-induced symptoms in airline passengers
JP2004121962A (ja) * 2002-10-01 2004-04-22 National Institute Of Advanced Industrial & Technology ナノバブルの利用方法及び装置
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
WO2005067865A1 (en) * 2004-01-15 2005-07-28 Oral Bioscience Pty. Limited Oral anaesthetic gel
CN101262852A (zh) * 2004-12-13 2008-09-10 麦克内尔-Ppc股份有限公司 稳定活性药物成分的组合物和方法
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
CA2612179C (en) * 2005-06-17 2016-08-02 Aft Pharmaceuticals Limited A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects

Also Published As

Publication number Publication date
EP2237767A1 (en) 2010-10-13
CN101938991A (zh) 2011-01-05
US20090280160A1 (en) 2009-11-12
CL2008003615A1 (es) 2009-10-16
TW200932208A (en) 2009-08-01
BRPI0820673A2 (pt) 2015-06-16
CA2709208A1 (en) 2009-06-18
CO6321221A2 (es) 2011-09-20
KR20100102632A (ko) 2010-09-24
RU2010127737A (ru) 2012-01-20
ZA201004654B (en) 2011-03-30
JP2011506337A (ja) 2011-03-03
WO2009076165A1 (en) 2009-06-18
PE20091084A1 (es) 2009-07-23
AU2008335464A1 (en) 2009-06-18
AR069572A1 (es) 2010-02-03

Similar Documents

Publication Publication Date Title
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
BR112013022044A2 (pt) veículo mastigável para absorção na boca
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
AU2008347158A8 (en) Oral pharmaceutical dosage forms
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
WO2008023016A3 (en) Galenic formulations of aliskiren
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MX2012000752A (es) Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos.
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
TN2010000135A1 (en) Galenical formulations of organic compounds
TW200621317A (en) Pharmaceutical composition
MX2011011126A (es) Composiciones y metodos para tratar quemaduras.
WO2013183062A3 (en) Palatable formulations of ibuprofen
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
UA116334C2 (uk) Тверді форми дозування бендамустину
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA99914C2 (ru) Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
MX2009010989A (es) Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.
MX339470B (es) Formulacion que contiene nicotina.
FR2902007B1 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SOLSTICE NEUROSCIENCES, INC.

FA Abandonment or withdrawal